Selected article for: "adaptive immunity and tumor necrosis"

Author: Angelopoulou, Athina; Alexandris, Nikos; Konstantinou, Evangelia; Mesiakaris, Konstantinos; Zanidis, Charilaos; Farsalinos, Konstantinos; Poulas, Konstantinos
Title: Imiquimod - A toll like receptor 7 agonist - Is an IDEAL OPTION for MANAGEMENT of COVID 19
  • Cord-id: 5lvrb7s3
  • Document date: 2020_6_23
  • ID: 5lvrb7s3
    Snippet: According to numerous recent publications, the COVID-19 patients have lymphopenia, higher infection-related biomarkers and several elevated inflammatory cytokines (i.e. tumor necrosis factor (TNF)-α, interleukin IL-2R and IL-6). The total number of B cells, T cells and NK cells are significantly decreased. RNA viruses, SARS-CoV-2 included, hit the innate immune system in order to cause infection, through TLRs 3, 7 and 8. Imiquimod is an immune-stimulator that activates TLR 7 and can be used to
    Document: According to numerous recent publications, the COVID-19 patients have lymphopenia, higher infection-related biomarkers and several elevated inflammatory cytokines (i.e. tumor necrosis factor (TNF)-α, interleukin IL-2R and IL-6). The total number of B cells, T cells and NK cells are significantly decreased. RNA viruses, SARS-CoV-2 included, hit the innate immune system in order to cause infection, through TLRs 3, 7 and 8. Imiquimod is an immune-stimulator that activates TLR 7 and can be used to enhance the innate and adaptive immunity. Preclinical and clinical trials are proposed.

    Search related documents:
    Co phrase search for related documents